1. Scrip
  2. >>Therapy Areas

SymBio shifts bendamustine's multiple myeloma focus to second-line use

 
• By Ian Haydock

SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.

SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma.

The Japanese venture initiated another Phase II study in 2010 investigating the alkylating agent in combination with prednisolone as a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.